Literature DB >> 26352882

High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo.

Marcel Yotebieng1, Andrew Edmonds, Patricia Lelo, Landry Kipula Wenzi, Papy Tshishikani Ndjibu, Jean Lusiama, Jean Pierre Kabuayi, Frieda Behets.   

Abstract

We assessed isoniazid preventive therapy (IPT) completion and predictors among HIV-infected children and adults in two HIV clinics in Kinshasa, Democratic Republic of Congo. Between 1 September 2012 and 15 June 2013, 546 children (1-15 years) and 1532 adults (>15 years) were initiated on IPT; 86.6% (408/470) of the children and 88.2% (1129/1280) of the adults with an IPT outcome completed their therapy. Patients on antiretroviral therapy at IPT initiation were more likely to complete IPT.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26352882      PMCID： PMC4566165          DOI： 10.1097/QAD.0000000000000791

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  14 in total

1.  The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.

Authors:  Betina Durovni; Solange C Cavalcante; Valeria Saraceni; Vitoria Vellozo; Giselle Israel; Bonnie S King; Silvia Cohn; Anne Efron; Antonio G Pacheco; Lawrence H Moulton; Richard E Chaisson; Jonathan E Golub
Journal:  AIDS       Date:  2010-11       Impact factor: 4.177

2.  Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV.

Authors:  Anand A Date; Marco Vitoria; Reuben Granich; Mazuwa Banda; Mayada Youssef Fox; Charlie Gilks
Journal:  Bull World Health Organ       Date:  2009-10-23       Impact factor: 9.408

3.  A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.

Authors:  C C Whalen; J L Johnson; A Okwera; D L Hom; R Huebner; P Mugyenyi; R D Mugerwa; J J Ellner
Journal:  N Engl J Med       Date:  1997-09-18       Impact factor: 91.245

4.  Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy.

Authors:  Appolinaire Tiam; Rhoderick Machekano; Celine R Gounder; Llang B M Maama-Maime; Keletso Ntene-Sealiete; Maitreyi Sahu; Anthony Isavwa; Oyebola Oyebanji; Allan Ahimbisibwe; Majoalane Mokone; Grace L Barnes; Richard E Chaisson; Laura Guay; Seble Kassaye
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

5.  Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.

Authors:  N A Halsey; J S Coberly; J Desormeaux; P Losikoff; J Atkinson; L H Moulton; M Contave; M Johnson; H Davis; L Geiter; E Johnson; R Huebner; R Boulos; R E Chaisson
Journal:  Lancet       Date:  1998-03-14       Impact factor: 79.321

6.  Mortality and associated factors after initiation of pediatric antiretroviral treatment in the Democratic Republic of the Congo.

Authors:  Steven F J Callens; Nicole Shabani; Jean Lusiama; Patricia Lelo; Faustin Kitetele; Robert Colebunders; Ziya Gizlice; Andrew Edmonds; Annelies Van Rie; Frieda Behets
Journal:  Pediatr Infect Dis J       Date:  2009-01       Impact factor: 2.129

7.  Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.

Authors:  A Mwinga; M Hosp; P Godfrey-Faussett; M Quigley; P Mwaba; B N Mugala; O Nyirenda; N Luo; J Pobee; A M Elliott; K P McAdam; J D Porter
Journal:  AIDS       Date:  1998-12-24       Impact factor: 4.177

8.  Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.

Authors:  P J Munseri; E A Talbot; L Mtei; C Fordham von Reyn
Journal:  Int J Tuberc Lung Dis       Date:  2008-09       Impact factor: 2.373

9.  The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study.

Authors:  Andrew Edmonds; Marcel Yotebieng; Jean Lusiama; Yori Matumona; Faustin Kitetele; Sonia Napravnik; Stephen R Cole; Annelies Van Rie; Frieda Behets
Journal:  PLoS Med       Date:  2011-06-14       Impact factor: 11.069

10.  Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules.

Authors:  Stanzi M le Roux; Mark F Cotton; Jonathan E Golub; David M le Roux; Lesley Workman; Heather J Zar
Journal:  BMC Med       Date:  2009-11-03       Impact factor: 8.775
View more
  7 in total

1.  Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART.

Authors:  B Maharaj; T N Gengiah; N Yende-Zuma; S Gengiah; A Naidoo; K Naidoo
Journal:  Int J Tuberc Lung Dis       Date:  2017-05-01       Impact factor: 2.373

2.  Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care.

Authors:  Khai Hoan Tram; Florence Mwangwa; Mucunguzi Atukunda; Asiphas Owaraganise; James Ayieko; Albert Plenty; Dalsone Kwariisima; Tamara D Clark; Maya L Petersen; Edwin D Charlebois; Moses R Kamya; Gabriel Chamie; Diane V Havlir; Carina Marquez
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-15       Impact factor: 3.731

3.  Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.

Authors:  Masanja Robert; Jim Todd; Bernard J Ngowi; Sia E Msuya; Angella Ramadhani; Veryhel Sambu; Isaya Jerry; Martin R Mujuni; Michael J Mahande; James S Ngocho; Werner Maokola
Journal:  BMC Infect Dis       Date:  2020-04-10       Impact factor: 3.090

4.  Drop-offs in the isoniazid preventive therapy cascade among children living with HIV in western Kenya, 2015-2019.

Authors:  Dickens Otieno Onyango; Marianne A B van der Sande; Courtney M Yuen; Jerphason Mecha; Daniel Matemo; Elizabeth Oele; John Kinuthia; Grace John-Stewart; Sylvia M LaCourse
Journal:  J Int AIDS Soc       Date:  2022-08       Impact factor: 6.707

5.  A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.

Authors:  Simon Sensalire; Esther Karungi Karamagi Nkolo; Juliana Nabwire; Anna Lawino; Dithan Kiragga; Martin Muhire; Herbert Kadama; Cordelia Katureebe; Proscovia Namuwenge; Joshua Musinguzi; Jacqueline Calnan; Dejene Seyoum
Journal:  AIDS Res Ther       Date:  2020-05-27       Impact factor: 2.250

6.  Low level of tuberculosis preventive therapy incompletion among people living with Human Immunodeficiency Virus in eastern Uganda: A retrospective data review.

Authors:  Paul Lwevola; Jonathan Izudi; Derrick Kimuli; Alimah Komuhangi; Stephen Okoboi
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-08-28

7.  Implementation of Isoniazid Preventive Therapy Among HIV-Infected Children at Health Facilities in Nairobi County, Kenya: A Cross-Sectional Study.

Authors:  Peninah M Mwangi; Dalton Wamalwa; Diana Marangu; Elizabeth M Obimbo; Murima Ng'ang'a
Journal:  East Afr Health Res J       Date:  2019-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.